Esophageal variceal bleeding: portal hypertension and portal vein thrombosis secondary to protein S deficiency - a case report. [PDF]
Sapkota P +5 more
europepmc +1 more source
Single‐cell DNA methylation (scDNAme) profiling maps epimutational clonal evolution, revealing mechanisms of malignancy and therapeutic resistance across diverse cancer types. By providing a high‐resolution landscape of intratumoral heterogeneity, these technologies empower precise patient stratification, guide the development of enhanced ...
Ik Soo Kim
wiley +1 more source
Internal thoracic artery aneurysm coincidental with protein S deficiency: a case report. [PDF]
Sano T +6 more
europepmc +1 more source
This review summarizes the transcription factors, repressive chromatin‐modifying complexes, and epigenetic mechanisms that control fetal hemoglobin repression. Notably, many regulators of γ‐globin silencing also function in transcriptional and epigenetic networks that drive cancer, highlighting opportunities to translate advances in hemoglobinopathy ...
Meigen Yu +3 more
wiley +1 more source
Protein S Levels to Guide Exon-Level Copy Number Variant Analysis of <i>PROS1</i> for Confirming Hereditary Protein S Deficiency: A 10-Year Single-Center Experience. [PDF]
Yu S +6 more
europepmc +1 more source
Protein S Deficiency and COVID-19: A Brutal Combination Leading to Acute Submassive Bilateral Pulmonary Embolism. [PDF]
Chirumamilla Y +3 more
europepmc +1 more source
CEACAM1 participation in breast cancer progression
In invasive breast cancer (BC), CEACAM1 shifts from an apical to a uniform membranous/cytoplasmic pattern, or is lost, as tumors dedifferentiate, inversely tracking the Ki‐67 proliferative index. In MCF‐7 cells, only CEACAM1‐4L suppresses proliferation, repressing cell cycle and growth factor genes.
Mykola Lyndin +3 more
wiley +1 more source
Moyamoya Syndrome (MMS) in a Patient With Sickle Cell Disease (SCD) and Protein S Deficiency. [PDF]
Saxena P +3 more
europepmc +1 more source
Pharmacological chromatin remodeling enhances response to estrogen therapy in ER+ breast cancer
Estrogen therapy elicits clinical benefit in ~ 30% of patients with endocrine‐resistant estrogen receptor (ER)‐positive breast cancer. Based on findings that ER transcriptional activation underlies response to estrogen therapy, we tested the effects of epigenetic dysregulation via pharmacological inhibition of histone deacetylases (HDACi).
Anneka L. Johnson Thomas +16 more
wiley +1 more source
Multidisciplinary Treatment for Multiple Dural Arteriovenous Fistulas/Arteriovenous Malformation Associated with Congenital Protein S Deficiency: A Case Report and Literature Review. [PDF]
Ogawa S +10 more
europepmc +1 more source

